Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma / 医学前沿

Autoimmune diseases (ADs) increase the risk of non-Hodgkin's lymphoma and contribute to poor prognosis of patients. However, the association between immunologic markers and clinical outcome has rarely been investigated. This study aims to analyze the prognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively reviewed the data on 502 patients with DLBCL treated in our institution from January 2013 to March 2018. Survival functions were estimated using Kaplan-Meier method and Cox regression model. The 3-year progression free survival (PFS) and overall survival (OS) rates were 70.2% and 80.9%, respectively, and the complete remission (CR) rate was 78.1%. Among the patients, those with multiple ( ⩾ 3) abnormal immunologic markers had significantly shorter 3-year PFS (52.7% vs. 77.3%, P 60 years for OS (P = 0.014). In conclusion, the immunologic status was closely related to lymphoma progression, and this study provides new insights into the risk stratification of patients with DLBCL.

Advances on molecular mechanism of B cell development related with lymphomagenesis in human germinal centres / 白血病·淋巴瘤

Germinal center is a site of B cell maturation and development, in which B cell activation and differentiation was regulated by inherent complexity signal and transcription factors networks. Under the normal condition, the interaction between these transcription factors maintain dynamic stability of B cell in germinal center. When cytogenetic abnormalities or viral infection appear, a variety of.abnormal expression of transcription factors induced the imbalance of B cell signal networks regulation. manifested as abnormal B cell proliferation, apoptosis, and differentiation was blocked. B cell malignancies were often associated with genetic change of B cell and abnormal expression of transcription factors.